Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy

Potential benefits in bone and breast

Lin H. Soe, Gregory T. Wurz, Chiao Jung Kao, Michael W. DeGregorio

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor agonist/antagonist, that was recently approved by the US Food and Drug Administration for the treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that affects up to 60% of postmenopausal women. Ospemifene is the first and only nonestrogen compound approved for this indication. Compared with other approved SERMs, such as tamoxifen, toremifene, bazedoxifene, and raloxifene, the estrogen-like effects of ospemifene in the vaginal epithelium are unique. This review first discusses the rationale for developing ospemifene, including its mechanism of action, and then focuses on the clinical development of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Included are discussions of the effects of ospemifene on the endometrium, serum lipids, coagulation markers, bone, and breast cancer. In conclusion, ospemifene is a SERM with a unique estrogen agonist/antagonist tissue profile that was recently approved in the US for the treatment of dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women. Ospemifene warrants further clinical investigation for the treatment and prevention of osteoporosis and breast cancer.

Original languageEnglish (US)
Pages (from-to)605-611
Number of pages7
JournalInternational Journal of Women's Health
Volume5
Issue number1
DOIs
StatePublished - Sep 25 2013

Fingerprint

Dyspareunia
Atrophy
Breast
Bone and Bones
Selective Estrogen Receptor Modulators
Therapeutics
Estrogens
Toremifene
Breast Neoplasms
Estrogen Antagonists
Bone Neoplasms
Ospemifene
United States Food and Drug Administration
Tamoxifen
Endometrium
Osteoporosis
Epithelium
Lipids

Keywords

  • Breast cancer
  • Dyspareunia
  • Ospemifene
  • Osteoporosis
  • Vulvar and vaginal atrophy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Maternity and Midwifery

Cite this

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy : Potential benefits in bone and breast. / Soe, Lin H.; Wurz, Gregory T.; Kao, Chiao Jung; DeGregorio, Michael W.

In: International Journal of Women's Health, Vol. 5, No. 1, 25.09.2013, p. 605-611.

Research output: Contribution to journalArticle

Soe, Lin H. ; Wurz, Gregory T. ; Kao, Chiao Jung ; DeGregorio, Michael W. / Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy : Potential benefits in bone and breast. In: International Journal of Women's Health. 2013 ; Vol. 5, No. 1. pp. 605-611.
@article{6493840208584b48b29ea09a30745845,
title = "Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: Potential benefits in bone and breast",
abstract = "Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor agonist/antagonist, that was recently approved by the US Food and Drug Administration for the treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that affects up to 60{\%} of postmenopausal women. Ospemifene is the first and only nonestrogen compound approved for this indication. Compared with other approved SERMs, such as tamoxifen, toremifene, bazedoxifene, and raloxifene, the estrogen-like effects of ospemifene in the vaginal epithelium are unique. This review first discusses the rationale for developing ospemifene, including its mechanism of action, and then focuses on the clinical development of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Included are discussions of the effects of ospemifene on the endometrium, serum lipids, coagulation markers, bone, and breast cancer. In conclusion, ospemifene is a SERM with a unique estrogen agonist/antagonist tissue profile that was recently approved in the US for the treatment of dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women. Ospemifene warrants further clinical investigation for the treatment and prevention of osteoporosis and breast cancer.",
keywords = "Breast cancer, Dyspareunia, Ospemifene, Osteoporosis, Vulvar and vaginal atrophy",
author = "Soe, {Lin H.} and Wurz, {Gregory T.} and Kao, {Chiao Jung} and DeGregorio, {Michael W.}",
year = "2013",
month = "9",
day = "25",
doi = "10.2147/IJWH.S39146",
language = "English (US)",
volume = "5",
pages = "605--611",
journal = "International Journal of Women's Health",
issn = "1179-1411",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy

T2 - Potential benefits in bone and breast

AU - Soe, Lin H.

AU - Wurz, Gregory T.

AU - Kao, Chiao Jung

AU - DeGregorio, Michael W.

PY - 2013/9/25

Y1 - 2013/9/25

N2 - Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor agonist/antagonist, that was recently approved by the US Food and Drug Administration for the treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that affects up to 60% of postmenopausal women. Ospemifene is the first and only nonestrogen compound approved for this indication. Compared with other approved SERMs, such as tamoxifen, toremifene, bazedoxifene, and raloxifene, the estrogen-like effects of ospemifene in the vaginal epithelium are unique. This review first discusses the rationale for developing ospemifene, including its mechanism of action, and then focuses on the clinical development of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Included are discussions of the effects of ospemifene on the endometrium, serum lipids, coagulation markers, bone, and breast cancer. In conclusion, ospemifene is a SERM with a unique estrogen agonist/antagonist tissue profile that was recently approved in the US for the treatment of dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women. Ospemifene warrants further clinical investigation for the treatment and prevention of osteoporosis and breast cancer.

AB - Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor agonist/antagonist, that was recently approved by the US Food and Drug Administration for the treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that affects up to 60% of postmenopausal women. Ospemifene is the first and only nonestrogen compound approved for this indication. Compared with other approved SERMs, such as tamoxifen, toremifene, bazedoxifene, and raloxifene, the estrogen-like effects of ospemifene in the vaginal epithelium are unique. This review first discusses the rationale for developing ospemifene, including its mechanism of action, and then focuses on the clinical development of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Included are discussions of the effects of ospemifene on the endometrium, serum lipids, coagulation markers, bone, and breast cancer. In conclusion, ospemifene is a SERM with a unique estrogen agonist/antagonist tissue profile that was recently approved in the US for the treatment of dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women. Ospemifene warrants further clinical investigation for the treatment and prevention of osteoporosis and breast cancer.

KW - Breast cancer

KW - Dyspareunia

KW - Ospemifene

KW - Osteoporosis

KW - Vulvar and vaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=84884870814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884870814&partnerID=8YFLogxK

U2 - 10.2147/IJWH.S39146

DO - 10.2147/IJWH.S39146

M3 - Article

VL - 5

SP - 605

EP - 611

JO - International Journal of Women's Health

JF - International Journal of Women's Health

SN - 1179-1411

IS - 1

ER -